NO821569L - Diagnostiseringsmetode og proevesett - Google Patents

Diagnostiseringsmetode og proevesett

Info

Publication number: NO821569L
Authority: NO; Norway
Prior art keywords: differentiated; antigenic; antigenic components; components; stated
Prior art date: 1980-09-24

Application number

NO821569A

Other languages

English (en)

Norwegian (no)

Inventor

Henry Anthony Erlich

Michael Alan Lovett

Original Assignee

Cetus Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-09-24

Filing date

1982-05-12

Publication date

1982-05-12

1982-05-12 Application filed by Cetus Corp filed Critical Cetus Corp

1982-05-12 Publication of NO821569L publication Critical patent/NO821569L/no

Links

238000000034 method Methods 0.000 title claims description 40
238000012360 testing method Methods 0.000 title claims description 27
108090000623 proteins and genes Proteins 0.000 claims description 85
102000004169 proteins and genes Human genes 0.000 claims description 70
230000000890 antigenic effect Effects 0.000 claims description 67
201000010099 disease Diseases 0.000 claims description 59
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
210000002966 serum Anatomy 0.000 claims description 43
238000006243 chemical reaction Methods 0.000 claims description 40
241000589884 Treponema pallidum Species 0.000 claims description 28
239000000758 substrate Substances 0.000 claims description 27
206010020751 Hypersensitivity Diseases 0.000 claims description 22
230000007815 allergy Effects 0.000 claims description 22
208000026935 allergic disease Diseases 0.000 claims description 21
238000003745 diagnosis Methods 0.000 claims description 19
150000004676 glycans Chemical class 0.000 claims description 14
229920001282 polysaccharide Polymers 0.000 claims description 14
239000005017 polysaccharide Substances 0.000 claims description 14
239000007787 solid Substances 0.000 claims description 11
238000012546 transfer Methods 0.000 claims description 9
238000001155 isoelectric focusing Methods 0.000 claims description 7
244000005700 microbiome Species 0.000 claims description 7
241000700605 Viruses Species 0.000 claims description 6
244000052769 pathogen Species 0.000 claims description 6
230000001717 pathogenic effect Effects 0.000 claims description 6
206010028980 Neoplasm Diseases 0.000 claims description 4
239000013566 allergen Substances 0.000 claims description 4
239000000126 substance Substances 0.000 claims description 4
238000001502 gel electrophoresis Methods 0.000 claims 3
239000000499 gel Substances 0.000 description 45
239000000427 antigen Substances 0.000 description 26
102000036639 antigens Human genes 0.000 description 24
108091007433 antigens Proteins 0.000 description 24
238000000211 autoradiogram Methods 0.000 description 22
208000006379 syphilis Diseases 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 10
201000005485 Toxoplasmosis Diseases 0.000 description 10
238000001962 electrophoresis Methods 0.000 description 10
229920002401 polyacrylamide Polymers 0.000 description 10
108090000765 processed proteins & peptides Proteins 0.000 description 10
239000000523 sample Substances 0.000 description 10
241000283973 Oryctolagus cuniculus Species 0.000 description 9
241000223996 Toxoplasma Species 0.000 description 9
241000223997 Toxoplasma gondii Species 0.000 description 8
238000001514 detection method Methods 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 8
241001529453 unidentified herpesvirus Species 0.000 description 8
108020004414 DNA Proteins 0.000 description 7
230000001154 acute effect Effects 0.000 description 7
239000000243 solution Substances 0.000 description 7
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
239000000020 Nitrocellulose Substances 0.000 description 6
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 6
ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 6
238000000376 autoradiography Methods 0.000 description 6
239000000872 buffer Substances 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
229910052740 iodine Inorganic materials 0.000 description 6
239000011630 iodine Substances 0.000 description 6
229920001220 nitrocellulos Polymers 0.000 description 6
229940079938 nitrocellulose Drugs 0.000 description 6
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
241000606161 Chlamydia Species 0.000 description 5
241000606153 Chlamydia trachomatis Species 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
238000000576 coating method Methods 0.000 description 5
230000004069 differentiation Effects 0.000 description 5
239000000463 material Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
241000588724 Escherichia coli Species 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
108060003951 Immunoglobulin Proteins 0.000 description 4
108010058846 Ovalbumin Proteins 0.000 description 4
241000700584 Simplexvirus Species 0.000 description 4
238000013019 agitation Methods 0.000 description 4
239000003659 bee venom Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
102000018358 immunoglobulin Human genes 0.000 description 4
238000011534 incubation Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
229940092253 ovalbumin Drugs 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
241000701022 Cytomegalovirus Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
229910001870 ammonium persulfate Inorganic materials 0.000 description 3
238000003149 assay kit Methods 0.000 description 3
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
239000004327 boric acid Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000012631 diagnostic technique Methods 0.000 description 3
ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 3
239000002245 particle Substances 0.000 description 3
208000009090 primary syphilis Diseases 0.000 description 3
230000002285 radioactive effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000009589 serological test Methods 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
206010056873 tertiary syphilis Diseases 0.000 description 3
238000005406 washing Methods 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
206010019973 Herpes virus infection Diseases 0.000 description 2
208000008306 Latent Syphilis Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
201000000860 Secondary syphilis Diseases 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
230000004520 agglutination Effects 0.000 description 2
230000000172 allergic effect Effects 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229940038705 chlamydia trachomatis Drugs 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000003599 detergent Substances 0.000 description 2
230000035931 haemagglutination Effects 0.000 description 2
229940072221 immunoglobulins Drugs 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
208000014479 late latent syphilis Diseases 0.000 description 2
239000010410 layer Substances 0.000 description 2
210000005265 lung cell Anatomy 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
239000012723 sample buffer Substances 0.000 description 2
238000002791 soaking Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
210000001550 testis Anatomy 0.000 description 2
VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
244000025254 Cannabis sativa Species 0.000 description 1
241001647378 Chlamydia psittaci Species 0.000 description 1
239000006145 Eagle's minimal essential medium Substances 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241001197893 Glyptemys herpesvirus Species 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
229920005479 Lucite® Polymers 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
YBOFEONRFJMHND-UHFFFAOYSA-N [Br].N#CC#N Chemical compound [Br].N#CC#N YBOFEONRFJMHND-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
238000003759 clinical diagnosis Methods 0.000 description 1
238000007374 clinical diagnostic method Methods 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000011229 interlayer Substances 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000003531 protein hydrolysate Substances 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
108700004121 sarkosyl Proteins 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)

NO821569A 1980-09-24 1982-05-12 Diagnostiseringsmetode og proevesett NO821569L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US19036180A	1980-09-24	1980-09-24
US29796281A	1981-09-02	1981-09-02

Publications (1)

Publication Number	Publication Date
NO821569L true NO821569L (no)	1982-05-12

Family

ID=26886027

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO821569A NO821569L (no)	1980-09-24	1982-05-12	Diagnostiseringsmetode og proevesett

Country Status (10)

Country	Link
EP (1)	EP0050424B1 (ja)
JP (1)	JPS57501692A (ja)
BR (1)	BR8108820A (ja)
CA (1)	CA1167376A (ja)
DE (1)	DE3172347D1 (ja)
DK (1)	DK232882A (ja)
ES (1)	ES8303072A1 (ja)
IL (1)	IL63907A0 (ja)
NO (1)	NO821569L (ja)
WO (1)	WO1982001011A1 (ja)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR231590A1 (es) *	1981-04-29	1984-12-28	Ciba Geigy Ag	Dispositivo de analisis inmunologico y procedimiento para obtenerlo
FI69639C (fi) *	1982-07-02	1986-03-10	Orion Yhtymae Oy	Preparat foer anvaendning vid klamydia-diagnostik
US4863729A (en) *	1984-06-20	1989-09-05	Linus Pauling Institute Of Science And Medicine	Method for preparing a macromolecular monoclonal antibody composition
US4647544A (en) *	1984-06-25	1987-03-03	Nicoli David F	Immunoassay using optical interference detection
DE3722273A1 (de) *	1986-07-08	1988-01-21	Bio Rad Laboratories	Festphasen-bindungsreagentien, ihre herstellung und sie enthaltende assay-kits
NZ221895A (en) *	1986-09-26	1990-09-26	Univ California	Composition and method for the diagnosis of pseudomonas aeruginosa infections
US6297027B1 (en)	1996-07-31	2001-10-02	Purina Mills, Inc.	Bovine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6277592B1 (en)	1996-07-31	2001-08-21	Purina Mills, Inc.	Porcine leptin protein, nucleic acid sequences coding therefor and uses thereof
US6171788B1 (en)	1997-01-28	2001-01-09	The Regents Of The University Of California	Methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6475724B1 (en)	1997-01-28	2002-11-05	The Regents Of The University Of California	Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US7138511B1 (en)	1997-01-28	2006-11-21	The Regents Of The University Of California	Nucleic acids, kits and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders
US6103468A (en) *	1997-10-07	2000-08-15	Labatt Brewing Company Limited	Rapid two-stage polymerase chain reaction method for detection of lactic acid bacteria in beer
WO2000079009A2 (en)	1999-06-22	2000-12-28	Invitrogen Corporation	Improved primers and methods for the detection and discrimination of nucleic acids
US6830902B1 (en)	1999-07-02	2004-12-14	Invitrogen Corporation	Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
US6692918B2 (en)	1999-09-13	2004-02-17	Nugen Technologies, Inc.	Methods and compositions for linear isothermal amplification of polynucleotide sequences
AU783873B2 (en)	1999-09-13	2005-12-15	Nugen Technologies, Inc.	Methods and compositions for linear isothermal amplification of polynucleotide sequences
ES2638112T3 (es)	1999-12-16	2017-10-18	Monsanto Technology, Llc	Nuevas construcciones de expresión en plantas
CN1498274A (zh)	2000-06-26	2004-05-19	Ŧب��˾	基于转录的核酸扩增方法和组合物
US7846733B2 (en)	2000-06-26	2010-12-07	Nugen Technologies, Inc.	Methods and compositions for transcription-based nucleic acid amplification
CA2436693A1 (en)	2000-12-11	2002-06-20	Alexion Pharmaceuticals, Inc.	Nested oligonucleotides containing hairpin for nucleic acid amplification
WO2002048402A2 (en)	2000-12-13	2002-06-20	Nugen Technologies, Inc.	Methods and compositions for generation of multiple copies of nucleic acid sequences and methods of detection thereof
US6794141B2 (en)	2000-12-22	2004-09-21	Arcturus Bioscience, Inc.	Nucleic acid amplification
US6635451B2 (en)	2001-01-25	2003-10-21	Abbott Laboratories	Desaturase genes and uses thereof
EP1366197B1 (en)	2001-03-09	2007-05-09	Nugen Technologies, Inc.	Methods and compositions for amplification of rna sequences
AU2002308633A1 (en)	2001-05-09	2002-11-18	Monsanto Technology Llc	Metabolite transporters
EP1950305A1 (en)	2001-05-09	2008-07-30	Monsanto Technology, LLC	Tyr a genes and uses thereof
US7291477B2 (en)	2001-07-03	2007-11-06	Xenotope Diagnostics, Inc.	Method and device for trichomonas detection
US7414111B2 (en)	2001-09-19	2008-08-19	Alexion Pharmaceuticals, Inc.	Engineered templates and their use in single primer amplification
DK1436404T3 (da)	2001-09-19	2010-03-08	Alexion Pharma Inc	Manipulerede templates og deres anvendelse i single-primer amplifikation
US20030165859A1 (en)	2001-10-23	2003-09-04	Invitrogen Corporation	Primers and methods for the detection and discrimination of nucleic acids
US7211656B2 (en)	2002-01-30	2007-05-01	Abbott Laboratories	Desaturase genes, enzymes encoded thereby, and uses thereof
WO2003096797A2 (en)	2002-05-15	2003-11-27	Monsanto Technology Llc	Method of increasing plant organ and seed size in a plant
AU2003240795A1 (en)	2002-05-24	2003-12-12	Invitrogen Corporation	Nested pcr employing degradable primers
US20050123924A1 (en)	2002-08-05	2005-06-09	Ayoub Rashtchian	Compositions for in vitro amplification of nucleic acids
US7205147B2 (en)	2002-09-23	2007-04-17	E.I. Du Pont De Nemours And Company	Nucleic acids encoding ryanodine receptors
US7094879B2 (en)	2002-10-02	2006-08-22	Abbott Laboratories	Genetically engineered P30 antigen, improved antigen cocktail, and uses thereof
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7402386B2 (en)	2003-04-14	2008-07-22	Nugen Technologies, Inc.	Global amplification using random priming by a composite primer
EP1699926B1 (en)	2003-12-10	2014-06-18	Monsanto Technology, LLC	Stress tolerant plants and methods thereof
ES2351973T3 (es)	2004-06-04	2011-02-14	Fluxome Sciences A/S	Células metabólicamente modificadas por ingeniería para la producción de ácidos grasos poliinsaturados.
US7456270B2 (en)	2004-09-01	2008-11-25	Abbott Laboratories	Δ6-desaturase genes and uses thereof
DE602005021525D1 (de)	2004-09-14	2010-07-08	Univ Colorado	R behandlung mit bucindolol
US7790363B2 (en)	2005-02-07	2010-09-07	Abbott Laboratories Inc.	Diagnostic test for vitamin B12
US8624027B2 (en)	2005-05-12	2014-01-07	Abbvie Inc.	Combination therapy for treating cancer and diagnostic assays for use therein
US8017103B2 (en)	2005-07-01	2011-09-13	Board Of Regents, The University Of Texas System	Methods and compositions to diagnose trichomonas infection
JP5203202B2 (ja)	2005-08-16	2013-06-05	メルロジェン，エルエルシー	メルル遺伝子の識別のための方法
WO2007030759A2 (en)	2005-09-07	2007-03-15	Nugen Technologies, Inc.	Improved nucleic acid amplification procedure
US7439028B2 (en)	2005-09-30	2008-10-21	Board Of Regents, The University Of Texas System	Methods and compositions to correlate Trichomonas infection with prostate cancer
RU2442793C2 (ru)	2005-11-30	2012-02-20	Эбботт Лэборетриз	АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
KR101667623B1 (ko)	2005-11-30	2016-10-19	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
US7803567B2 (en)	2005-12-09	2010-09-28	Board Of Regents, The University Of Texas System	Methods and compositions for detecting trichomonas in a sample contacted with fixative
US7285388B1 (en)	2006-04-07	2007-10-23	Merlogen, Llc	Methods for identification of alport syndrome
US8933209B2 (en)	2006-04-26	2015-01-13	Abbvie Inc.	Dep2 and its uses in major depressive disorder and other related disorders
AR061180A1 (es)	2006-05-25	2008-08-13	Monsanto Technology Llc	Metodo para identificar loci de caracteristicas cuantitativas de resistencia a enfermedades en soja y composiciones de los mismos
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Method for the treatment of amyloidoses
CL2008002553A1 (es)	2007-08-29	2009-09-04	Monsanto Technology Llc	Metodo de mejoramiento de plantas mediante la introduccion de loci de caracteristicas cuantitativas asociadas con resistencia a la mancha foliar gris.
US20090203531A1 (en)	2008-02-12	2009-08-13	Nurith Kurn	Method for Archiving and Clonal Expansion
US8030471B2 (en)	2008-03-06	2011-10-04	Abbott Laboratories	Plasmodium malariae and Plasmodium ovale genes and uses thereof
US8268981B2 (en)	2008-03-06	2012-09-18	Abbott Laboratories	Plasmodium malariae and plasmodium ovale genes and uses thereof
GB2470672B (en)	2008-03-21	2012-09-12	Nugen Technologies Inc	Methods of RNA amplification in the presence of DNA
US8669414B2 (en)	2008-04-24	2014-03-11	Monsanto Technology Llc	Method to identify Asian soybean rust resistance quantitative trait loci in soybean and compositions thereof
JP5723281B2 (ja)	2008-10-06	2015-05-27	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	デルタ−８デサチュラーゼ遺伝子、それによってコードされる酵素およびそれらの使用
US8288124B2 (en)	2008-11-20	2012-10-16	Abbott Laboratories	Cloning, expression and purification of recombinant porcine intrinsic factor for use in diagnostic assay
US9084781B2 (en)	2008-12-10	2015-07-21	Novartis Ag	MEK mutations conferring resistance to MEK inhibitors
CA2749945A1 (en)	2009-01-31	2010-08-05	Abbott Laboratories	Markers to predict and monitor response to aurora kinase b inhibitor therapy
MX2011008488A (es)	2009-02-11	2011-10-24	Abbott Lab	Metodos y composiciones para identificar, clasificar y monitorear individuos que tienen tumores y canceres resistentes al inhibidor de la familia de bcl-2.
US8063193B2 (en)	2009-03-27	2011-11-22	Abbott Laboratories	Nucleotide and amino acid sequences encoding an exported protein 1 derived from Plasmodium vivax and uses thereof
CN102483415B (zh)	2009-05-14	2015-09-09	代表亚利桑那大学的亚利桑那校董会	基于odc1基因型的癌诊断与治疗
EP2448960A1 (en)	2009-06-30	2012-05-09	Abbott Laboratories	Markers of xmrv infection and uses thereof
US8188335B2 (en)	2009-07-17	2012-05-29	Abbott Laboratories	Δ9-elongase for production of polyunsaturated fatty acid-enriched oils
US9512481B2 (en)	2009-09-11	2016-12-06	The Regents Of The University Of Colorado, A Body Corporate	Polymorphisms in the PDE3A gene
CA2822747A1 (en)	2009-12-23	2011-06-30	Arca Biopharma, Inc.	Use of s-(6-nitro-oxi-hexahydro-furo[3,2-b]thioacetate in the treatment of cardiovascular disorders associated with oxide synthase dysfunction
MX360932B (es)	2010-02-25	2018-11-21	Dana Farber Cancer Inst Inc	Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
MX343368B (es)	2010-03-09	2016-11-01	The Broad Inst Inc *	Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer.
MX360403B (es)	2010-04-15	2018-10-31	Abbvie Inc	Proteinas de union a amiloide beta.
EP2568978B1 (en)	2010-05-14	2019-04-24	Arizona Board of Regents on Behalf of University of Arizona	Cancer prevention and treatment based on dietary polyamine content
BR112012030838A2 (pt)	2010-06-09	2016-11-08	Dana Faber Cancer Inst Inc	molécula de ácido nucléico isolada que codifica uma proteína mek1 mutante tendo atividade de mek1, vetor de expressão, célula hospedeira, método de produzir uma prote ína mek1 mutante, proteína mek1 mutante isolada, método de identificar um paciente que tem câncer, método de orimizar o tratamento de um paciente que tem câncer,e, uso de um inibidor de raf e de um inibidor de mek.
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
US20120058461A1 (en)	2010-08-18	2012-03-08	Abbott Laboratories	Molecular detection of xmrv infection
US20120058462A1 (en)	2010-08-18	2012-03-08	Abbott Laboratories	Molecular detection of xmrv infection
US10172305B2 (en)	2011-04-29	2019-01-08	Monsanto Technology Llc	Diagnostic molecular markers for seed lot purity traits in soybeans
EP2750495B1 (en)	2011-08-31	2019-02-27	Seminis Vegetable Seeds, Inc.	Methods and compositions for watermelon firmness
US10314253B2 (en)	2012-12-04	2019-06-11	Seminis Vegetable Seeds, Inc.	Methods and compositions for watermelon sex expression
US10294489B2 (en)	2013-03-15	2019-05-21	Board Of Trustees Of Southern Illinois University	Soybean resistant to cyst nematodes
US10059999B2 (en)	2013-06-10	2018-08-28	Monsanto Technology Llc	Molecular markers associated with soybean tolerance to low iron growth conditions
NZ718164A (en)	2013-11-27	2017-04-28	Seminis Vegetable Seeds Inc	Disease resistance loci in onion
EP3107373A4 (en)	2014-02-21	2017-11-08	Syngenta Participations AG	Genetic loci associated with increased fertility in maize
NZ630710A (en)	2014-02-27	2016-03-31	Seminis Vegetable Seeds Inc	Compositions and methods for peronospora resistance in spinach
US10316369B2 (en)	2014-06-27	2019-06-11	Seminis Vegetable Seeds, Inc.	Methods and assays for male sterile watermelon
EP3005862A1 (en)	2014-10-10	2016-04-13	Seminis Vegetable Seeds, Inc.	Melon plants with improved disease tolerance
US10448595B2 (en)	2015-09-03	2019-10-22	Seminis Vegetable Seeds, Inc.	Downy mildew resistant lettuce plants
EP3199642A1 (en)	2016-02-01	2017-08-02	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Plant breeding using high throughput sequencing
SG11201808306PA (en)	2016-03-24	2018-10-30	Tragara Pharmaceuticals Inc	Treatment of cancer with tg02
MX2018012379A (es)	2016-04-12	2019-07-04	Univ Michigan Regents	Degradadores de proteinas de bromodominio y dominioextraterminal (bet).
EP3512853B1 (en)	2016-09-13	2020-12-23	The Regents of The University of Michigan	Fused 1,4-diazepines as bet protein degraders
AU2017326171B2 (en)	2016-09-13	2021-12-09	The Regents Of The University Of Michigan	Fused 1,4-oxazepines as BET protein degraders
AU2017232187B2 (en)	2016-09-30	2023-11-09	Seminis Vegetable Seeds, Inc.	Xanthomonas resistant brassica oleracea plants
CA3072746A1 (en)	2017-08-14	2019-02-21	Epizyme, Inc.	Methods of treating cancer by inhibiting setd2
MX2020001875A (es)	2017-08-18	2020-07-29	Tragara Pharmaceuticals Inc	Forma polimorfica de tg02.
WO2019055444A1 (en)	2017-09-13	2019-03-21	The Regents Of The University Of Michigan	DEGRADATION AGENTS OF BROMODOMAIN BET PROTEIN WITH CLEAR BINDERS
EP3863720A1 (en)	2018-10-08	2021-08-18	The Regents Of The University Of Michigan	Small molecule mdm2 protein degraders
CA3145881A1 (en)	2019-01-15	2020-07-23	Seminis Vegetable Seeds, Inc.	Green bean plants with improved resistance to sclerotinia sclerotiorum and genetic markers therefor
AU2020291936A1 (en)	2019-06-12	2022-02-03	Vanderbilt University	Dibenzylamines as amino acid transport inhibitors
CN114222729A (zh)	2019-06-12	2022-03-22	范德比尔特大学	氨基酸转运抑制剂及其用途
SG10202008262UA (en)	2019-09-26	2021-04-29	Seminis Vegetable Seeds Inc	Lettuce plants having resistance to nasonovia ribisnigri biotype nr:1
AU2021204717A1 (en)	2020-07-15	2022-02-03	Seminis Vegetable Seeds, Inc.	Green Bean Plants with Improved Disease Resistance
US20230193310A1 (en)	2021-12-10	2023-06-22	Seminis Vegetabe Seeds, Inc.	Lettuce plants having resistance to downy mildew
US20230404003A1 (en)	2022-06-21	2023-12-21	Seminis Vegetable Seeds, Inc.	Novel qtls conferring resistance to cucumber mosaic virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3941876A (en) *	1973-04-25	1976-03-02	Gte New Ventures Corporation	In vitro method for determining allergic hypersensitivity
FR2233024A1 (en) *	1973-06-15	1975-01-10	Greyward Lab Interconti	Treponema haemagglutination test - using tanned avian erythrocytes as carrier for ireponema antigen
US3979509A (en) *	1974-09-03	1976-09-07	General Electric Company	Opaque layer method for detecting biological particles
US3952091A (en) *	1974-10-23	1976-04-20	Hoffmann-La Roche Inc.	Simultaneous multiple radioimmunoassay
US4237224A (en) *	1974-11-04	1980-12-02	Board Of Trustees Of The Leland Stanford Jr. University	Process for producing biologically functional molecular chimeras
US4094759A (en) *	1975-01-03	1978-06-13	Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.	Method for simultaneous quantitative analysis of several constituents in a sample
US4097149A (en) *	1975-02-03	1978-06-27	Aladjem Frederick J	Quantitative protein analysis by immunodiffusion
FR2353856A1 (fr) *	1976-06-02	1977-12-30	Chateau Guy	Ruban destine a servir de support a une reaction par exemple chimique ou biochimique, et procede d'analyse le mettant en oeuvre
US4294817A (en) *	1977-11-25	1981-10-13	International Diagnostic Technology, Inc.	Method of fluoro immunoassay
DK138080A (da) *	1979-04-02	1980-10-03	Research Corp	Fremgangsmaade til serologisk undersoegelse af kilder som mistaenkes for at indeholde antistoffer mod chlamydia trachomatis

1981
- 1981-09-22 BR BR8108820A patent/BR8108820A/pt unknown
- 1981-09-22 JP JP56503335A patent/JPS57501692A/ja active Pending
- 1981-09-22 WO PCT/US1981/001272 patent/WO1982001011A1/en active Application Filing
- 1981-09-22 IL IL63907A patent/IL63907A0/xx unknown
- 1981-09-23 ES ES505713A patent/ES8303072A1/es not_active Expired
- 1981-09-24 DE DE8181304411T patent/DE3172347D1/de not_active Expired
- 1981-09-24 CA CA000386624A patent/CA1167376A/en not_active Expired
- 1981-09-24 EP EP81304411A patent/EP0050424B1/en not_active Expired
1982
- 1982-05-12 NO NO821569A patent/NO821569L/no unknown
- 1982-05-24 DK DK232882A patent/DK232882A/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE3172347D1 (en)	1985-10-24
EP0050424B1 (en)	1985-09-18
DK232882A (da)	1982-05-24
ES505713A0 (es)	1983-02-01
ES8303072A1 (es)	1983-02-01
IL63907A0 (en)	1981-12-31
BR8108820A (pt)	1982-08-24
WO1982001011A1 (en)	1982-04-01
JPS57501692A (ja)	1982-09-16
CA1167376A (en)	1984-05-15
EP0050424A1 (en)	1982-04-28

Publication	Publication Date	Title
NO821569L (no)	1982-05-12	Diagnostiseringsmetode og proevesett
Teysseire et al.	1992	Comparison of Western immunoblotting and microimmunofluorescence for diagnosis of Mediterranean spotted fever
Gussenhoven et al.	1997	LEPTO dipstick, a dipstick assay for detection of Leptospira-specific immunoglobulin M antibodies in human sera
Clements et al.	1983	Serodiagnosis of Rocky Mountain spotted fever: comparison of IgM and IgG enzyme-linked immunosorbent assays and indirect fluorescent antibody test
Karlsson et al.	1989	Comparison of Western blot and enzyme-linked immunosorbent assay for diagnosis of Lyme borreliosis
Kim et al.	1993	Rapid diagnosis of scrub typhus by a passive hemagglutination assay using recombinant 56-kilodalton polypeptides
Nielsen et al.	1987	An enzyme labelled nuclear antigen immunoassay for detection of cytomegalovirus IgM antibodies in human serum: specific and non‐specific reactions
Robinson et al.	1993	Analysis of the humoral response to the flagellin protein of Borrelia burgdorferi: cloning of regions capable of differentiating Lyme disease from syphilis
US10859575B2 (en)	2020-12-08	Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates
Rauer et al.	1998	Enzyme-linked immunosorbent assay using recombinant OspC and the internal 14-kDa flagellin fragment for serodiagnosis of early Lyme disease
US5643733A (en)	1997-07-01	Borrelia burgdorferi antigens and uses thereof
Dettori et al.	1989	Evaluation of Western immunoblotting technique in the serological diagnosis of human syphilitic infections
Karlsson	1990	Western immunoblot and flagellum enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis
EP0165658A2 (en)	1985-12-27	Methods and compositions for detection of legionnaires disease
EP1240519B1 (en)	2007-01-31	Compositions and methods for detecting treponema pallidum
Verhofstede et al.	1989	Comparison of six commercial enzyme linked immunosorbent assays for detecting IgM antibodies against Toxoplasma gondii.
US5374520A (en)	1994-12-20	Assay method for Epstein-Barr virus antibodies
Rauer et al.	1995	Establishment of enzyme-linked immunosorbent assay using purified recombinant 83-kilodalton antigen of Borrelia burgdorferi sensu stricto and Borrelia afzelii for serodiagnosis of Lyme disease
Cutler et al.	1994	Predictive value of serology in diagnosing Lyme borreliosis.
WO1996007910A1 (fr)	1996-03-14	Substance pour le diagnostic de l'infection par le chlamydia
Jones et al.	1993	Enzyme-linked immunosorbent assay for detection of human immunoglobulin G to lipopolysaccharide of spotted fever group rickettsiae
GONEN et al.	1993	Serum reactivity to Chlamydia trachomatis and C. pneumoniae antigens in patients with documented infection and in healthy children by microimmunofluorescence and immunoblotting techniques
Wos et al.	1986	Immunoglobulin isotypes of anti-Trichomonas vaginalis antibodies in patients with vaginal trichomoniasis
Cutler et al.	1993	Simplified method for the interpretation of immunoblots for Lyme borreliosis
CA2603794A1 (en)	2006-10-26	Syphilis diagnostic test and kits